Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings

AMARIN CORP PLCUK

Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.
Global restructuring to cut operating costs by ~$70M annually; expects $30-37M in restructuring charges in Q2 2025.
Company retains U.S. rights; nearly $300M cash on hand, no debt; accelerated path to positive cash flow.
Agreement term 15 years, auto-renewal subject to commercialization in at least one country.

item 1.01item 2.05item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.